Table 4.

Summary of clinical responses according to FLT3 mutation status



Patients, no. (%)
Response
All patients
Patients not receiving hydroxyurea
FLT3 mutant patients
FLT3 wild-type patients
Complete remission   0 (0)   0 (0)   0 (0)   0 (0)  
Partial remission   0 (0)   0 (0)   0 (0)   0 (0)  
Bone marrow response   5 (19)   5 (22)   0 (0)   5 (23)  
Hematologic response   3 (11)   1 (4)   3 (60)   0 (0)  
No response   14 (52)   13 (57)   1 (20)   13 (59)  
Progressive disease
 
5 (19)
 
4 (17)
 
1 (20)
 
4 (18)
 


Patients, no. (%)
Response
All patients
Patients not receiving hydroxyurea
FLT3 mutant patients
FLT3 wild-type patients
Complete remission   0 (0)   0 (0)   0 (0)   0 (0)  
Partial remission   0 (0)   0 (0)   0 (0)   0 (0)  
Bone marrow response   5 (19)   5 (22)   0 (0)   5 (23)  
Hematologic response   3 (11)   1 (4)   3 (60)   0 (0)  
No response   14 (52)   13 (57)   1 (20)   13 (59)  
Progressive disease
 
5 (19)
 
4 (17)
 
1 (20)
 
4 (18)
 

Total number of patients was 27; 23 of whom did not receive hydroxyurea. There were 5 FLT3 mutant patients and 22 FLT3 wild-type patients.

or Create an Account

Close Modal
Close Modal